Pfizer acquires rights to investigational overactive bladder drug

April 20, 2006

Pfizer, Inc. has entered into an agreement with Schwarz Pharma AGunder which Pfizer will acquire worldwide rights to fesoterodine, anew drug candidate for the treatment of overactive bladder.

Pfizer, Inc., has entered into an agreement with Schwarz Pharma AG under which Pfizer will acquire worldwide rights to fesoterodine, a new drug candidate for the treatment of overactive bladder.

The agreement settles all existing and potential fesoterodine patent litigation between the parties worldwide. It is subject to clearance by U.S. Federal Trade Commission.